Medios : 240506 Medios AG Quarterly Statement Q1 2024 final geschuetzt

Group Quarterly Statement

as of March 31, 2024

-Eigenkapitalveränderungsrechnung

Quarterly statement as of March 31, 2024

Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance

• Revenue increases by 5.8% to €456.2 million in the first quarter
• Cash flow from operating activities increases to €43.4 million
• Closing of the Ceban acquisition planned for May 2024
• Guidance 2024 confirmed: Significant increase in revenue and margin expected

Medios AG ("Medios"), the leading provider of Specialty Pharma solutions in Germany, confirms its guidance for the 2024 financial year after a solid first quarter. Revenue increased by 5.8% year-on-year to €456.2 million in the period from January to March 2024 (previous year: €431.2 million). At €15.1 million (previous year: €15.0 million), EBITDA pre reached the level of the same quarter of the previous year. As a result, the EBITDA pre margin of 3.3% (previous year: 3.5%) was slightly lower than in the same period of the previous year. Cash flow from operating activities improved significantly.

Significant events in the reporting period

Acquisition of the Dutch market leader for pharmaceutical compounding services

Medios announced the acquisition of Ceban Pharmaceuticals B.V. ("Ceban") on March 18, 2024. Ceban is a fast-grow- ing, leading pharmaceutical compounding platform with operations in the Netherlands, Belgium and Spain. In 2023, Ceban is expected to generate revenue of approximately €160m and an adjusted EBITDA of approximately €29m, which corresponds to an adjusted EBITDA margin of approximately 18%. The acquisition is an important step in Me- dios' growth strategy, which aims to build the leading European Specialty Pharma platform. Through the acquisition, Medios is well positioned to benefit from the strong growth in home care, clinics and hospitals in the Netherlands and Belgium. The closing of the transaction is subject to the fulfillment of customary closing conditions. The transaction is expected to be completed in May 2024.

Ceban is the market leader in pharmaceutical compounding in the Netherlands, among the top 3 in Belgium and among the top 5 in Spain. The company supplies around 3,300 pharmacies and more than 200 hospitals and has its own pharmacy chain with 23 pharmacies in the Netherlands.

Ceban covers the entire value chain - from the procurement of APIs (Active Pharmaceutical Ingredients) to the sterile and non-sterile compounding of pharmaceuticals and the supply of public and hospital pharmacies through to homecare services for patients at home. The company has long-standing relationships with players along the entire value chain and is well positioned to benefit from the rapidly growing demand for pharmaceutical compounding by clinics, pharmacies and hospitals.

Medios will acquire a 100% stake in Ceban Pharmaceuticals B.V. from funds managed by Bencis. The purchase price to be paid for the transaction includes a cash component of €235.3m and 1.7 million new Medios shares. The newly issued shares will be subject to a strict hard lock-up period of 24 months.

The purchase price will be financed by Medios from existing cash and an already committed credit line. The 1.7 million new shares will be issued from authorized capital in return for a non-cash contribution.

2

Group Quarterly Statement as of March 31, 2024 - Medios

Contracts with members of the Executive Board

On February 1, 2024, the Supervisory Board of Medios AG resolved to extend the existing Executive Board contracts of Mi-Young Miehler (Chief Operating Officer / COO) and Christoph Prußeit (Chief Innovation Officer / CINO) ahead of schedule until January 31, 2026 and July 31, 2027 respectively. Mi-Young Miehler has been a member of the Executive Board since July 1, 2017 and is responsible for the Pharmaceutical Supply business segment as well as for the departments Marketing & Corporate Communications, Human Resources and Post Merger Integration. Christoph Prußeit has been a member of the Executive Board since January 1, 2019 and is responsible for the departments IT, IT Security and Project Management as well as Digital Innovation, Public Affairs and Privacy. He is also responsible for the Patient- Specific Therapies business segment.

The Supervisory Board of Medios AG has appointed Constantijn van Rietschoten as further member to the Company's Executive Board with effect from May 1, 2024. In his new role as Chief International Markets, van Rietschoten, who has been Head of International Business Development at Medios since April 2023, will assume responsibility for the entire international business and its further development. He has been appointed as a member of the Executive Board until April 30, 2027.

Earnings, financial and asset situation of the Medios Group

EARNINGS OF THE MEDIOS GROUP (IFRS)

In the first three months of the 2024 financial year, consolidated revenue at Medios Group increased by €25.0 m or 5.8% to €456.2 m compared to the same period of the previous year. Revenue was generated almost exclusively within the Federal Republic of Germany, as in the previous year.

In the first quarter, the Pharmaceutical Supply segment generated external revenue of €401.0m (previous year: €368.1m), which corresponds to an increase of €32.9m or 8.9% compared to the same period of the previous year. External revenue in the Patient-Specific Therapies segment decreased by €7.9m or 12.5% year on year to €55.1m (previous year: €62.9m), with around €3.5m of this decline attributable to the sale of Kölsche Blister GmbH in June 2023. In addition, regulatory price adjustments in the areas of gastroenterology and oncology as well as higher performance -related expenses for the acquisition of compounding volumes had a negative impact on revenue in the first quarter. External revenue of €0.1m (previous year: €0.2m) was generated in the Services segment.

Gross profit for the Group amounted to € 27.6 m in the reporting period, compared to €27.8m in the same period of the previous year, which corresponds to a decrease of €0.2m or 0.9% and a gross profit margin of 6.1% (previous year: 6.5%).

In the Pharmaceutical Supply segment, gross profit rose by €1.1m to €15.0m (previous year: €13.9m), which corresponds to a significant increase of 7.9%. At 3.4%, the gross profit margin was largely on the same level as in the previous year (previous year: 3.5%). In the Patient-Specific Therapies segment, gross profit fell, driven by revenue, by € 1.6 m or 11.1% to €12.5m (previous year: €14.0m), with €0.7m of this decline attributable to the sale and resulting deconsoli- dation of Kölsche Blister GmbH. The gross profit margin increased by 2.5 percentage points from 18.5% to 21.0% compared to the same period in the previous year, which was also due to higher other operating income and the increase in the manufacture of ophthalmic products.

The Group's personnel costs fell by a total of €0.4m or 4.2% year-on-year to €8.6m (previous year: €9.0m), which is mainly due to the change in the scope of consolidation in the previous year. Non-cash expenses for stock option programs included in personnel expenses amounted to €0.3m in the first quarter (previous year: €0.4m).

The Group's other operating expenses amounted to €7.3m in the first quarter of 2024, an increase of €1.7m or 30.2% compared to the previous year (previous year: €5.6m). This development was mainly due to a €1.2m increase in legal and consulting costs (previous year: €0.6m), which were mainly incurred as part of the acquisition process for Ceban

3

Group Quarterly Statement as of March 31, 2024 - Medios

Pharmaceuticals B.V. Due to the sale of Kölsche Blister GmbH, other operating expenses fell by €0.2m compared to the previous year.

The Group's earnings before interest, taxes, depreciation and amortization (EBITDA) fell by €1.6m or 11.7% compared to the previous year and is reconciled as follows to the consolidated earnings before interest, taxes, depreciation and amortization (EBITDA pre) adjusted for special items:

EBITDA pre of the Medios Group increased by €0.1m or 0.8% compared to the same period of the previous year.

The operating segment Pharmaceutical Supply contributed EBITDA pre of €11.0m to Group EBITDA pre and achieved an increase in earnings of €0.9m or 9.0% compared to the previous year (previous year: €10.1m). EBITDA pre adjusted for special items in the Patient-Specific Therapies operating segment decreased by €0.6million or 9.4% year-on-year to €5.9m (previous year: €6.6m), which is mainly due to regulatory price adjustments. The sale of Kölsche Blister GmbH had no significant effect on the change in EBITDA pre compared to the previous year. EBITDA pre in the Services business segment amounted to €-1.9m and is essentially unchanged compared to the same period of the previous year (previous year: €-1.7m).

Depreciation and amortization in the first quarter of 2024 amounted to €5.2m and thus remained largely unchanged compared to the same period of the previous year (previous year: €5.3m).

The Medios Group's financial result decreased by €0.3m compared to the same period of the previous year to €-0.7m (previous year: €-0.4m) and mainly includes interest expenses for utilized tranches of the existing syndicated loan and commitment interest for the secured bridge financing.

FINANCIAL SITUATION OF THE MEDIOS GROUP (IFRS)

Cash and cash equivalents amounted to €112.7m as of March 31, 2024 (December 31, 2023: €71.0m) and mainly consisted of freely available bank balances. The increase in cash and cash equivalents of €41.7m compared to the end of 2023 is attributable to the following significant cash flows:

Cash flow from operating activities amounted to €43.4m in the first quarter of 2024 (Q1 2023: €-25.3 m) and mainly resulted from the positive operating result of €11.7m and a reporting date-related increase in trade payables of €31.4m, while inventories and trade receivables remained almost unchanged compared to the end of 2023.

Cash flow from investing activities amounted to €-0.4m in the first quarter of 2024 (Q1 2023: €-17.2m) and mainly resulted from investments in property, plant and equipment.

Cash flow from financing activities amounted to €-1.3m in the first quarter of 2024 (Q1 2023: €-24.1m) and mainly resulted from interest paid in the amount of €0.4 m as well as repayments of financial liabilities in the amount of €0.3m and financial liabilities from rental agreements in the amount of €0.6m.

4

Group Quarterly Statement as of March 31, 2024 - Medios

ASSET SITUATION OF THE MEDIOS GROUP (IFRS)

The Group's total assets as at March 31, 2024 increased by €36.1m to €630.8m compared to December 31, 2023 (December 31, 2023: €594.8m), which is mainly due to an increase in current assets and current liabilities.

Intangible assets decreased by a total of €3.9m as of 31 March 2024 compared to December 31, 2023, which is attributable to the amortization of customer bases and other intangible assets in the amount of €3.7m.

Property, plant and equipment and capitalized right-of-use assets from rental agreements decreased compared to December 31, 2023 due to scheduled depreciation in the amount of €1.5m.

Current assets increased by €40.8m to €310.0m (December 31, 2023: €269.2m). As of the reporting date, this is mainly

due to a significant increase in cash and cash equivalents of €41.7m to €112.7m (December 31, 2023: €71.0m). Other assets decreased by €1.4m compared to the end of 2023.

Equity amounted to €473.1m as of March 31, 2024, which corresponds to an increase of €4.3m compared to the end of 2023 (December 31, 2023: €468.8m). The equity ratio was 75.0% as of March 31, 2024 (December 31, 2023: 78.8%).

Positive outlook for the 2024 financial year

The Executive Board expects revenue of €1.9bn to €2.1bn and EBITDA pre of €82m to €91m for 2024. This expectation is based on the assumption that the acquisition of Ceban Pharmaceuticals B.V. will be completed by the beginning of May 2024 and that the Group will be fully consolidated from this date. The forecast is based on a number of assumptions about the future. If key assumptions do not materialize, an adjustment of the forecast cannot be ruled out. The extraordinary expenses adjusted in the EBITDA pre-forecast for 2024 include expenses for share options and for M&A, expenses for the introduction of an ERP system and performance-related payments for the acquisition of compounding volumes in 2024 in the amount of €5.7m.

In the medium term, the market share in the area of patient-specific therapies in particular is to be further expanded, thereby increasing the profitability of the entire Medios Group. Accordingly, Medios is aiming for consolidated revenue of more than €2bn and an EBITDA pre-margin at least in the mid-single-digit range in the medium term.

EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock options and expenses for M&A activities as well as for performance-related payments for the acquisition of compounding volumes and, from 2024, for expenses for the introduction of an ERP system.

5

Group Quarterly Statement as of March 31, 2024 - Medios

Group Quarterly Statement as of March 31, 2024 - Medios

Group Quarterly Statement as of March 31, 2024 - Medios

Group Quarterly Statement as of March 31, 2024 - Medios

9

Group Quarterly Statement as of March 31, 2024 - Medios

10

Group Quarterly Statement as of March 31, 2024 - Medios